683 Capital Management’s Eucrates Biomedical Acquisition Corp. Warrant EUCRW Stock Holding History

683 Capital Management’s Portfolio EUCRW Stock Details EUCRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-196,348	Closed	-$7.95K	–	308
2023 Q1	$7.95K	Hold	196,348	–	–	﹤0.01%	276
2022 Q4	$10.9K	Sell	196,348 -3,652	-2%	-$130	﹤0.01%	269
2022 Q3	$8K	Hold	200,000	–	–	﹤0.01%	224
2022 Q2	$13K	Hold	200,000	–	–	﹤0.01%	241
2022 Q1	$37K	Hold	200,000	–	–	﹤0.01%	314
2021 Q4	$116K	Hold	200,000	–	–	﹤0.01%	298
2021 Q3	$142K	Hold	200,000	–	–	0.01%	185
2021 Q2	$208K	Hold	200,000	–	–	0.01%	181
2021 Q1	$250K	Buy	+200,000	New	+$324K	0.01%	148

683 Capital Management's EUCRW Position: Q2 2023 in Review

683 Capital Management sold out of Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) in Q2 2023, closing a stake of 196,348 shares — an estimated $7.95K sold.

683 Capital Management first reported a position in EUCRW in Q1 2021 and held it in 9 quarters. The position peaked at $250K in Q1 2021. 0 funds tracked by Wall St. Rank hold EUCRW as of Q2 2023.

683 Capital Management reported no remaining Eucrates Biomedical Acquisition Corp. Warrant position as of Q2 2023 after selling out during the quarter.
683 Capital Management sold 196,348 Eucrates Biomedical Acquisition Corp. Warrant shares in Q2 2023, an estimated $7.95K.
683 Capital Management first reported a position in Eucrates Biomedical Acquisition Corp. Warrant in Q1 2021 and held it in 9 quarters.
683 Capital Management's Eucrates Biomedical Acquisition Corp. Warrant position peaked at $250K in Q1 2021.
0 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Warrant as of Q2 2023.

Based on 683 Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.